The European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable ...

Cambridge: AstraZeneca has announced that the Company's Imfinzi (durvalumab) in combination with chemotherapy has been ...

AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer indication in the United States. Imfinzi is approved in combination with ...

AstraZeneca (AZ) has announced that its Imfinzi (durvalumab)-based perioperative regimen has been approved by the European ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s IMFINZI ® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

Imfinzi in combination with chemotherapy has been approved in the European Union, EU, for the treatment of adults with ...

EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...

Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the bladder) has ...

Meanwhile, the FDA has approved AstraZeneca’s Imfinzi as a perioperative treatment for muscle-invasive bladder cancer, marking it as the first immunotherapy for this condition. This approval was ...

Imfinzi in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy ...

The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...